Skip to main content
. 2023 Jun 25;201(2):215–225. doi: 10.1007/s10549-023-06999-9

Table 3.

The use of neoadjuvant systemic therapy by intrinsic subtype

Characteristic HR−/HER2−, N = 35a HR−/HER2+, N = 5a HR+/HER2−, N = 397a HR+/HER2+, N = 52a Unknown, N = 11a p-valueb
Neoadjuvant treatment administered 26 (74.3%) 3 (60.0%) 101 (25.4%) 32 (61.5%) 3 (27.3%)  < 0.001
Neoadjuvant chemotherapy administered 26 (74.3%) 2 (40.0%) 89 (22.4%) 32 (61.5%) 2 (18.2%)  < 0.001

an (%)

bFisher’s exact test

HR Hormonal receptors, HER2 Human epidermal growth factor receptor 2